Latest Biogen Idec Stories
Array planning for potential return of MEK inhibitor BOULDER, Colo., Aug. 12, 2014 /PRNewswire/ -- Array BioPharma Inc.
Biogen Idec's Tecfidera is Forecast to Overtake Teva's Copaxone Franchise as the U.S. Market Leader by 2015, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
- 'Clinical Map Initiative' On Track; Human Proof of Concept Results for RG-101 and Nomination of Third Clinical Candidate Expected by YE 2014 - LA JOLLA, Calif., Aug.
-- ENDEAR Trial To Enroll 110 SMA Infants at Sites Globally CARLSBAD, Calif., Aug. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
MarketOptimizer.org adds “Multiple Sclerosis Global Clinical Trials Review, H2, 2014” to its store.
RICHMOND, Calif., July 23, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass.,
RICHMOND, Calif., July 16, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Editor Note: For more information about this release, please scroll to bottom. LONDON, July 7, 2014 /PRNewswire/ -- On Thursday, July 03, 2014, the NASDAQ Composite
- The parings of haberdine; also, any kind of fragments.